**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)ATTY DOCKET NO.
11068-015-999APPLICATION NO
10/612,600APPLICANT
Parkin et al.FILING DATE
July 1, 2003GROUP
1645 1649**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
2	A01	5,436,131	7/25/95	Condra et al.			
	A02	5,837,464	11/17/98	Capon et al.			
	A03	6,033,902	3/7/00	Haseltine et al.			
	A04	6,103,462	8/15/00	Paulous et al.			
10	A05	6,242,187	6/5/01	Capon et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
8	A06	WO99/67427	6/99	PCT			
	A07	Int'l Search Report for PCT/US03/21335	5/3/04	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

2	A08	Genbank Accession Number P12497 POL Polypeptide (2004)
	A09	Genbank Accession Number AF324493 HIV-1 vector pNL4....[gi:12831134] (2001).
	A10	Gervaix, et al., (1997), "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility <i>in Vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 94: 4653-4658.
	A11	Gunthard, et al., (1998), "Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1 <i>pol</i> From Clinical Samples," <i>Aids Research and Human Retroviruses</i> , 14(10): 869-876.
	A12	Herrmann, et al., (1997), "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity," <i>Ann. NY Acad Sciences</i> , 284: 632-637.
	A13	Hertogs, et al., (1998), "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs," <i>Antimicrobial Agents and Chemotherapy</i> , 42(2): 269-276.
	A14	Hirsch, et al., (2000), "Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection" <i>JAMA</i> , 283(18): 2417-26.
	A15	Petropoulos, et al., (2000), "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1," <i>Antimicrobial Agents and Chemotherapy</i> , 44(4): 920-928.
	A16	Race, et al., (1999), "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies," <i>AIDS</i> , 13(15): 2061-2068.
	A17	Schuurman, et al., (1999), "Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>Journal of Clinical Microbiology</i> , 37(7): 2291-2296.
	A18	Shi, et al., (1997), "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 41(12): 2781-85.
10	A19	Zieman, et al., (2000), "A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir," <i>Journal of Virology</i> , 74(9): 4414-4419.

EXAMINER

DATE CONSIDERED

10/16/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

07/14/04

Sheet 1 of 3



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

11068-015-999

APPLICATION NO

10/612,600

APPLICANT

Parkin *et al.*

FILING DATE

July 1, 2003

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B01	5,766,842	6/98	Melnick <i>et al.</i>			
	B02	20020064838	5/02	Parkin <i>et al.</i>			
	B03	20030108857	6/03	Parkin <i>et al.</i>			


FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B04	WO00/78996	12/00	PCT				
	B05	WO02/22076	3/02	PCT				
	B06	WO02/068618	9/02	PCT				
	B07	WO02/099387	12/02	PCT				
	B08	WO03/070700	8/03	PCT				
	B09	WO04/003512	1/04	PCT				
	B10	WO04/003514	1/04	PCT				
	B11	Int'l Search Report for PCT/US00/17178	12/00	PCT				
	B12	Int'l Search Report for PCT/US01/28754	3/02	PCT				
	B13	Int'l Search Report for PCT/US02/01682	9/02	PCT				
	B14	Int'l Search Report for PCT/US02/18684	1/03	PCT				
	B15	Int'l Search Report for PCT/US03/04362	12/04	PCT				
	B16	Int'l Search Report for PCT/US03/21023	7/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	B17	Carrillo <i>et al.</i> , (1998), "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor," <i>Journal of Virology</i> , 72(9): 7532-41.
	B18	Condra <i>et al.</i> , (1996), "Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor," <i>Journal of Virology</i> , 70(12): 8270-76
	B19	Craig <i>et al.</i> , 1998 "HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy", <i>AIDS</i> , 12: 1611-1618.
	B20	Dreyer GB, <i>et al.</i> "A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically" <i>Biochemistry</i> (1993) 32:937-947
	B21	J. Eron, <i>et al.</i> , (1995) Preliminary Assessment of 141 W94 in Combination with Other Protease Inhibitors," <i>5th Conference on Retroviruses and Opportunistic Infections</i> :
	B22	Gong <i>et al.</i> , (2000), "In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632," <i>Antimicrobial Agents and Chemotherapy</i> , 44(9): 2319-26.
		Hambright <i>et al.</i> (2001) "CTC-575: A Randomized Prospective Study of Phenotype Testing Versus Standard of

✓	B24	Hill, A. <i>et al.</i> (1998) "Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavar," <i>Int. Conf. AIDS</i> 12:812, (Abstract No. 6)
	B25	Katzenstein <i>et al.</i> , (2002), "Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364," Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection," 2002 9 th Conference on Retroviruses and Opportunistic Infections, Session 77 Poster Session 591-T.
	B26	Katzenstein <i>et al.</i> , (2002), "The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy," 2002 9 th Conference on Retroviruses and Opportunistic Infections, Session 28 Poster Session 129.
	B27	Kempf <i>et al.</i> , (2001), "Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate With Reduced Susceptibility to the Protease Inhibitor Lopinavir Among Viral Isolates From Protease Inhibitor-Experienced Patients," <i>Journal of Virology</i> , 75(16): 7462-69.
	B28	Kim, (1995) "Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme," <i>J. Am. Chem. Soc.</i> , 117: 1181-1182
	B29	Lambert DM, <i>et al.</i> (1992) "Human Immunodeficiency Virus Type 1 Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells" <i>Anit Microb Agents Chem</i> 36:982-98
	B30	Larder, <i>et al.</i> , (1995) "Potential Mechanism for; Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy," <i>Science</i> , 269; 696-699
	B31	Lazdins, <i>et al.</i> , (1997) "In Vitro Effect of al-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study wits Other Relevant HIV Protease Inhibitors," <i>J Infec. Dis.</i> , 175: 1063-1070
	B32	Livingston, <i>et al.</i> , (1995) "Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Humar Immunodeficiency Virus Therapy," <i>J Infec. Dis.</i> , 172:1.238-124
	B33	Maguire <i>et al.</i> , (2002), "Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 46(3): 731-738.
	B34	Mahalingam, <i>et al.</i> , (1999) "Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease," <i>Biochem.</i> , 263: 1-9
	B35	Miller M, <i>et al.</i> (1989) "Structure of Complex of Synthetic HIV-1j Protease with a SubstrateBased Inhibitor at 2.3 A Resolution, <i>Science</i> 246:1149-1152
	B36	Mohri H, <i>et al.</i> (1993) "Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients," <i>PNAS</i> 90:25-29
	B37	Murphy, <i>et al.</i> , (1999) "Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection" <i>J. Infec. Dis.</i> , 179: 808-81 E
	B38	Najera I, <i>et al.</i> (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates," <i>Aids Res Hum Retroviruses</i> 10:1479-1488
	B39	Najera I, <i>et al.</i> (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in Virus From Patients Undergoing No Drug Therapy," <i>J Virol</i> 69:23-31
	B40	Palmer, <i>et al.</i> , (1999) "Highly Drug-resistant HIV-1 Clinical Isolates Are Cross-resistant to Many Antiretroviral Compounds in Current Clinical Development," <i>AIDS</i> , 13: 661-667
	B41	Parkin, <i>et al.</i> , (1999) "Phenotypic changes in Drug Susceptibility Associated with Failure of Human Immunodeficiency Virus Type 1 (HIV-1) Triple Combination Therapy," <i>J Infec. Dis.</i> , 180: 865-870
	B42	Partaledis, <i>et al.</i> , (1995) "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Isolates with Reduced Sensitivity to Hydroxyethylamino Sulfonamide Inhibitors of HIV-1 Aspartyl Protease," <i>Journal of Virology</i> , 69: 5228-5235
	B43	Patick, <i>et al.</i> , (1998) "Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir," <i>Antimicrobial Agents and Chemotherapy</i> , 42(10): 2637-44.
	B44	Petit SC, <i>et al.</i> (1993) "The Specificity of the HIV-1 Protease" <i>Drug Discov Des</i> 1:69-83
	B45	Roberts NA, <i>et al.</i> (1990) "Rational Design of Peptide-Based HIV Proteinase" <i>Science</i> 248:358361
	B46	Roberts, N. A., (1995) "Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors," <i>AIDS</i> 9 (supp 2) S27-S32
	B47	Rusconi, Stefano. <i>et al.</i> (2000): "Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived From Patients with Multidrug Resistance to Other Protease Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 44(5): 1328-32.
	B48	Sadler, <i>et al.</i> , (1999) "Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults," <i>Antimicrobial Agents and Chemotherapy</i> , 43: 1686-1692
▼	B49	Sarkar, <i>et al.</i> , (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis," <i>BioTech</i> 8(4):404-407
	B50	Smidt, <i>et al.</i>, (1996) "A Mutation in Human Immunodeficiency Virus Type 1 Protease at Position 88, Located Outside

B52	Tian, <i>et al.</i> , (1998) "Zidovudine/Lamivudine Co-resistance Is Preceded by a Transient Period of Zidovudine Hypersensitivity," 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 30
B53	Tisdale, M. <i>et al.</i> (1995): "Cross-Resistance Analysis of Human Immunodeficiency Virus Type 1 Variants Individually Selected for Resistance to Five Different Protease Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> 39(8):1704-10.
B54	Tisdale, M. <i>et al.</i> (1998): "Genotypic and phenotypic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy," <i>Int. Conf AIDS</i> 12:583 (Abstract No. 32312)
B55	Tucker, <i>et al.</i> , (1998) "Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance Within Unselected Virus Populations In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 42: 478-480
B56	Young <i>et al.</i> J. Infect. Disease 178(5) 1497-1501 (1998)
B57	Andrew Chin, March 14, 2002 "On the Preparation and Utilization of Isolated and Purified Oligonucleotides," Produced on March 9, 2002 and contributed to the Public Collection of the Katherine R. Everett Law Library of the University of North Carolina. (Electronic Copy provided on CD-Rom)
EXAMINER 	
DATE CONSIDERED 10/16/06	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	